Sosipatros Boikos MD
Cancer Genetics/Cancer Risk Assessment, Endocrine Cancer, Sarcoma
Medical Oncologist, Co-Leader, Sarcoma Working Group, Washington Hospital Center, Georgetown University Hospital, Georgetown Lombardi Comprehensive Sarcoma Group
Join to View Full Profile
110 Irving St NWWashington, DC 20010
Phone+1 240-418-8300
Dr. Boikos is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2008 - 2011
University of Crete School of Health SciencesClass of 2002
Certifications & Licensure
VA State Medical License 2014 - 2026
DC State Medical License 2021 - 2024
MD State Medical License 2011 - 2014
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Venetoclax and Irinotecan in Relapsed/Refractory SCLC Start of enrollment: 2021 Jun 30
Publications & Presentations
PubMed
- Genomic Profiling Uncovers a Broader Spectrum of Dermatofibrosarcoma Protuberans: Implications for Diagnosis and Therapy.Steven Christopher Smith, Kieran Sweeney, Mark G Evans, Kartik Angara, Celia Reynolds
Modern Pathology. 2025-04-01 - 146 citationsRecurrent epimutation of SDHC in gastrointestinal stromal tumors.J. Keith Killian, Markku Miettinen, Robert L. Walker, Yonghong Wang, Yuelin Jack Zhu
Science Translational Medicine. 2014-12-24 - Thyroid hormone inactivation in gastrointestinal stromal tumorsSosipatros A. Boikos, Lee J. Helman, Constantine A. Stratakis
The New England Journal of Medicine. 2014-07-03
Journal Articles
- The Ewing Family of Tumors Rely on BCL-2 and BCL-XL to Escape PARP Inhibitor ToxicitySteven C Smith, Sosipatros A Boikos, Anthony C Faber, Clinical Cancer Research
- Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug TargetAaron N Hata, Sosipatros A Boikos, Anthony C Faber, Clinical Cancer Research
Press Mentions
What Is a Sarcoma? Tips for Navigating This Rare Type of CancerFebruary 24th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
